In den USA erhielt Genentech die Zulassung für Rituxan in drei weiteren Indikationen, darunter zur Erstbehandlung des follikulären Lymphoms. ###>In the US Genentech received marketing approvals for three additional indications for Rituxan, including treatment of previously untreated follicular lymphoma.